New Treatments for Frontal Fibrosing Alopecia
For frontal fibrosing alopecia (FFA), start with oral dutasteride 0.15-0.5 mg daily combined with intralesional triamcinolone acetonide injections, and if inflammation persists after 3-6 months, add hydroxychloroquine to the regimen. This multimodal approach addresses the irreversible nature of follicular scarring and targets both androgen-mediated and inflammatory pathways 1, 2.
First-Line Treatment Algorithm
Initial Therapy (Start Immediately Upon Diagnosis)
Oral Dutasteride:
- Start with 0.15-0.5 mg daily (more potent than finasteride as it inhibits both type I and II 5α-reductase)
- Women of childbearing potential require strict contraception for at least 6 months after discontinuation due to teratogenic risk 3
- Superior to finasteride in younger women (<50 years) for central and vertex sites 3
Plus Intralesional Triamcinolone Acetonide:
- Inject directly into areas of active inflammation
- Targets the lymphocytic inflammatory component destroying follicular stem cells 2, 4
Add-On Therapy if Inflammation Persists (3-6 months)
Hydroxychloroquine:
- Add if disease activity continues despite initial therapy
- Has anti-inflammatory and immunomodulatory effects
- One of the three treatments with highest level of evidence for FFA 1, 4
Emerging and Adjunctive Treatments
JAK Inhibitors (Tofacitinib)
Recent case reports demonstrate significant hair regrowth when tofacitinib is added to dutasteride and intralesional steroids in early, active FFA 2. Randomized controlled trials are currently in progress 5. This represents a promising new option for refractory cases, though evidence remains limited to case reports.
Oral Isotretinoin for Facial Papules
For the resistant facial papules that commonly accompany FFA, oral isotretinoin shows noticeable improvement where other treatments fail 6. This addresses a specific cosmetic concern that significantly impacts quality of life, though evidence is limited to retrospective studies and case series.
Platelet-Rich Fibrin (PRF)
PRF appears promising as a safe adjunctive treatment, particularly in mild cases and as an adjunct to hair transplantation 7. The 2025 guidelines suggest:
- 3 sessions, 1 month apart
- 5-7 mL PRF per session
- 0.05-0.1 mL/cm² dosing
- No activation required before injection 7
However, evidence quality remains controversial with highly variable study protocols 7.
Critical Distinctions from Female Pattern Hair Loss
Important caveat: The provided evidence predominantly addresses female pattern hair loss (FPHL), NOT frontal fibrosing alopecia. These are distinct entities:
- FPHL is non-scarring androgenetic alopecia where topical minoxidil is first-line 3
- FFA is a scarring (cicatricial) alopecia requiring more aggressive systemic therapy from the outset 1, 5
The treatment paradigm differs fundamentally because FFA causes irreversible follicular destruction, making early aggressive intervention critical 1, 2.
Treatments to Avoid
Contraindicated cosmetic procedures in FFA patients:
- Deep chemical peels (can induce facial scarring)
- Ablative laser therapies (risk of triggering scarring)
- Certain cosmetic ingredients may trigger or worsen FFA 8
Safe cosmetic options:
- Non-ablative lasers for facial vein prominence
- Autologous fat injections for atrophic indentations 8
Monitoring and Expectations
Realistic goals: Disease stabilization rather than regrowth, given the scarring nature 4. Early diagnosis and immediate treatment initiation are paramount to prevent irreversible follicular loss 5.
Treatment duration: Prolonged therapy (minimum 12 months) is necessary to assess response 1, 4.
Key pitfall: Delaying systemic therapy while attempting topical treatments alone—this is appropriate for FPHL but inadequate for the aggressive, scarring nature of FFA 1.